The U.S. Administration recently confirmed officials met with suppliers to discuss the manufacturing, distribution, and accessibility of Respiratory Syncytia Virus (RSV) immunizations through the private market.
On November 27, 2023, senior administration officials underscored the importance of manufacturers such as Sanofi and AstraZeneca working to meet demand with a sense of urgency.
Read More
